Aigen Investment Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Aigen Investment Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,515	Closed	-$371K	–	774
2022 Q1	$371K	Buy	4,515 +1,076	+31%	+$110K	0.06%	328
2021 Q4	$483K	Buy	+3,439	New	+$534K	0.03%	640
2021 Q3	–	Sell	-4,105	Closed	-$663K	–	697
2021 Q2	$663K	Sell	4,105 -2,248	-35%	-$361K	0.12%	193
2021 Q1	$1.09M	Buy	6,353 +1,862	+41%	+$369K	0.14%	162
2020 Q4	$986K	Sell	4,491 -1,738	-28%	-$376K	0.13%	206
2020 Q3	$1.03M	Buy	+6,229	New	+$852K	0.13%	244
2020 Q1	–	Sell	-1,845	Closed	-$238K	–	1646
2019 Q4	$238K	Buy	+1,845	New	+$178K	0.04%	505

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Aigen Investment Management's MRTX Position: Q2 2022 in Review

Aigen Investment Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2022, closing a stake of 4,515 shares — an estimated $371K sold.

Aigen Investment Management first reported a position in MRTX in Q4 2019 and held it in 7 quarters. The position peaked at $1.09M in Q1 2021. 230 funds tracked by Wall St. Rank hold MRTX as of Q2 2022.

Aigen Investment Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Aigen Investment Management sold 4,515 Mirati Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $371K.
Aigen Investment Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2019 and held it in 7 quarters.
Aigen Investment Management's Mirati Therapeutics, Inc. Common Stock position peaked at $1.09M in Q1 2021.
230 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Aigen Investment Management's 13F filing for Q2 2022, filed 2 Aug 2022.